Human Metabolome Technologies America, Inc.

Human Metabolome Technologies America, Inc. provides metabolomic and lipidomic analytical testing services to the National Institutes of Health as a prime contractor, competing in full-and-open procurements without set-aside designation. The firm is self-certified as a small disadvantaged business and operates from Allston, Massachusetts, though source descriptions identify it as Japan-based; it competes entirely as a prime on small purchase orders under primary PSC Reference Laboratory Testing and NAICS codes in biotechnology research and development and testing laboratory services.

Human Metabolome Technologies America concentrates heavily on NIH biomedical research customers. The top five funding agencies account for 86% of awards by count and 90% by potential value, with the National Cancer Institute dominating both metrics at 35 awards worth $464 thousand combined potential value. The National Heart Lung and Blood Institute (10 awards, $123 thousand), the National Institute on Drug Abuse (5 awards, $369 thousand), the National Institute of Child Health and Human Development (3 awards, $56 thousand), and the National Institute on Alcohol Abuse and Alcoholism (2 awards, $37 thousand) complete the active set. The dollar rankings diverge slightly from volume — the National Institute on Drug Abuse carries higher average award values than the National Heart Lung and Blood Institute — but the National Cancer Institute anchors both dimensions decisively.

The vendor's capability portfolio centers on metabolomic and lipidomic analysis, basic-scan metabolomics, liquid chromatography–mass spectrometry (LC-MS and CE-MS) data acquisition, and laboratory testing services in support of cancer, substance abuse, heart and lung disease, child health, and craniofacial research programs. Representative work includes a $24,220 samples-analysis purchase order from the National Institute of Child Health and Human Development awarded February 2025, a $23,520 laboratory testing order from the National Cancer Institute for August–November 2023, a $19,500 metabolomics and lipidomics analysis service order from the National Institute on Alcohol Abuse and Alcoholism for March–June 2022, and a $17,000 metabolomic analytical services order from the National Institute on Alcohol Abuse and Alcoholism awarded June 2026 with completion by June 2027. All awards are firm fixed-price purchase orders; no parent IDVs, GWACs, BPAs, or master service agreements appear in the source.

Activity has been sparse and episodic. Sixty-four awards over twelve years of sourcing data (2014–2026) yielded only one award each in 2025 and 2026, down from a three-award 2021. Only one award faces ultimate completion inside the next twenty-four months ($17 thousand, the June 2026 NIAAA order), presenting minimal recompete exposure in that window. The vendor holds no subcontract footprint in the source data — all sixty-four awards are prime contracts — and sits on no named federal vehicles or consortia relationships.